IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.440
+0.040 (2.86%)
At close: Apr 2, 2026, 4:00 PM EDT
1.530
+0.090 (6.25%)
After-hours: Apr 2, 2026, 7:43 PM EDT
IN8bio Employees
IN8bio had 17 employees as of December 31, 2025. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,143,529
Market Cap
14.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| Lantern Pharma | 24 |
| BioCardia | 20 |
| SeaStar Medical Holding | 19 |
| Genenta Science | 13 |
| Cocrystal Pharma | 11 |
| Traws Pharma | 7 |
| Intensity Therapeutics | 7 |
INAB News
- 21 days ago - IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 - GlobeNewsWire
- 5 weeks ago - IN8bio to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer - GlobeNewsWire
- 2 months ago - IN8bio to Present at Upcoming Investor and Scientific Conferences in February - GlobeNewsWire
- 2 months ago - IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma - GlobeNewsWire
- 3 months ago - IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager - GlobeNewsWire
- 5 months ago - IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewsWire